Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Table 1 Baseline data between the two groups

Baseline data	Compaq group (n = 48)	Ranibizumab group (n = 48)	t/χ2 value	P value
Age (yr)	64.8 ± 7.2	66.3 ± 6.9	-1.042	0.300
BMI (kg/m2)	23.5 ± 2.3	23.2 ± 2.8	0.574	0.568
Before treatment: BCVA (LogMAR)	0.78 ± 0.12	0.80 ± 0.11	-0.851	0.397
Gender, n (%)			2.043	0.153
Male	27 (56.25)	20 (41.67)
Female	21 (43.75)	28 (58.33)
Distribution of affected side, n (%)			0.667	0.414
Left	22 (45.83)	26 (54.17)
Right	26 (54.17)	22 (45.83)

BCVA: Best corrected visual acuity.